<DOC>
	<DOCNO>NCT02427724</DOCNO>
	<brief_summary>This study conduct split-face -body randomize control trial compare lidocaine 2.5 % /prilocaine 2.5 % topical anesthetic ( LPTA ) , lidocaine 7 % /tetracaine 7 % topical anesthetic ( LTTA ) , placebo vechicle ( PV ) patient ' pain perception Q-switched 532nm laser treatment lentigo and/or photorejuvenation.Subjects fill pain score visual analog scale ( VAS ) 0 pain 10 pain treatment area complete .</brief_summary>
	<brief_title>The Effect Topical Anesthetics Patients ' Pain Operative Experience During Treatment With QSwitched Laser</brief_title>
	<detailed_description />
	<mesh_term>Lentigo</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<mesh_term>Prilocaine</mesh_term>
	<mesh_term>Tetracaine</mesh_term>
	<mesh_term>Anesthetics , Local</mesh_term>
	<mesh_term>Anesthetics</mesh_term>
	<criteria>1 . Patients moderate lentigo and/or photodamage desire laser tone . 2 . Females 2565 year age . 3 . In good health . 4 . Have Fitzpatrick phototype IIII . 5 . Willingness ability understand provide inform consent communicate investigator/study staff . 1 . Younger 25 old 65 year age . 2 . Pregnant lactating . 3 . Is male . 4 . Has receive follow treatment face : ablative nonablative laser procedure past 3 month radiofrequency device treatment past 3 month ultrasound device treatment past 3 month medium deep chemical peel past 3 month 5 . Has active infection face upper inner arm ( exclude mild acne ) . 6 . Is allergic lidocaine , tetracaine , prilocaine . 7 . Has kidney disease and/or liver disease . 8 . Has G6PD and/or pseudocholinesterase deficiency . 9 . Is take class I antiarrhythmic medication . 10 . Is tan . 11 . Has history hyperpigmentation laser treatment . 12 . Has mental illness . 13 . Has history chronic pain condition fibromyalgia vulvodynia . 14 . Unable understand protocol give inform consent . 15 . Multiply recurrent episode cold sore . 16 . Any significant skin disease beyond mild acne . 17 . Any condition would , professional opinion investigator , potentially affect response participation clinical clinical study , would pose unacceptable risk subject .</criteria>
	<gender>Female</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>